Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Total Current Liabilities: 2019-2024

Historic Total Current Liabilities for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to $29.1 million.

  • 4D Molecular Therapeutics' Total Current Liabilities rose 25.94% to $37.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.1 million, marking a year-over-year increase of 25.94%. This contributed to the annual value of $29.1 million for FY2024, which is 53.81% up from last year.
  • According to the latest figures from FY2024, 4D Molecular Therapeutics' Total Current Liabilities is $29.1 million, which was up 53.81% from $19.0 million recorded in FY2023.
  • In the past 5 years, 4D Molecular Therapeutics' Total Current Liabilities ranged from a high of $29.1 million in FY2024 and a low of $15.7 million during FY2022.
  • Moreover, its 3-year median value for Total Current Liabilities was $19.0 million (2023), whereas its average is $21.3 million.
  • As far as peak fluctuations go, 4D Molecular Therapeutics' Total Current Liabilities dropped by 3.72% in 2022, and later skyrocketed by 53.81% in 2024.
  • Yearly analysis of 5 years shows 4D Molecular Therapeutics' Total Current Liabilities stood at $16.7 million in 2020, then dropped by 2.42% to $16.3 million in 2021, then decreased by 3.72% to $15.7 million in 2022, then increased by 20.47% to $19.0 million in 2023, then surged by 53.81% to $29.1 million in 2024.